Search

Xenon Pharmaceuticals Inc

Avatud

SektorTervishoid

41.21 2.36

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

39.88

Max

41.09

Põhinäitajad

By Trading Economics

Sissetulek

-8.4M

-111M

Aktsiakasum

-1.15

Töötajad

358

EBITDA

978K

-111M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+77.64% upside

Turustatistika

By TradingEconomics

Turukapital

-2.4B

3.6B

Eelmine avamishind

38.85

Eelmine sulgemishind

41.21

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. nov 2026, 23:02 UTC

News

Xenon Pharmaceuticals reports a Q3 net loss of $110.4 million, better than the expected $113 million loss, with operating expenses rising to $120.1 million.

6. nov 2026, 21:03 UTC

Xenon Pharmaceuticals Inc. is trading higher, diverging from a downward shift in the broader market despite recent upward momentum in prior sessions.

5. nov 2026, 22:11 UTC

Xenon Pharmaceuticals Inc. is trading lower in after-market hours amid a broader market decline.

4. nov 2026, 21:07 UTC

Xenon Pharmaceuticals Inc. gained significantly during Wednesday's trading, maintaining strong upward momentum and finishing above its 20-day moving average since Tuesday's close.

3. nov 2026, 21:07 UTC

Xenon Pharmaceuticals Inc. is trading higher, maintaining a strong position above its 20-day moving average and near the upper end of its one-month range.

2. nov 2026, 20:52 UTC

Xenon Pharmaceuticals Inc. is trading modestly higher, positioned above its 20-day moving average and near the upper end of its one-month range.

30. okt 2026, 20:08 UTC

Social Media
News

Stifel sets a price target of $86 for Xenon Pharmaceuticals and maintains a "Buy" rating, citing the company's developing pipeline for epilepsy treatments.

29. okt 2026, 20:04 UTC

News
Social Media

Xenon Pharmaceuticals reports positive Phase 1 results for XEN1701 and XEN1120, supporting progression to Phase 2 studies in acute pain, presented at IASP 2026.

28. okt 2026, 19:36 UTC

Xenon Pharmaceuticals Inc. is seeing a modest advance on Wednesday, marking three consecutive sessions of gains despite a slight pullback from its mid-morning peak.

27. okt 2026, 20:07 UTC

Xenon Pharmaceuticals Inc. is trading modestly higher, settling in the middle of its one-month trading range after a brief dip earlier in the day.

23. okt 2026, 20:01 UTC

Xenon Pharmaceuticals Inc shares are declining, reversing recent gains and reflecting a downward shift since Thursday's close.

22. okt 2026, 19:41 UTC

Xenon Pharmaceuticals Inc is experiencing higher price movement, supported by significant gains in the Biotechnology sub-sector, trading within the middle of its one-month range.

21. okt 2026, 23:46 UTC

Xenon Pharmaceuticals Inc shares are trading lower in after-market hours, following a notable drop from an earlier high amid broader market weakness.

20. okt 2026, 20:02 UTC

Xenon Pharmaceuticals Inc shares are advancing, having reached a peak earlier in the session, marking a significant increase within its one-month trading range.

19. okt 2026, 20:02 UTC

Xenon Pharmaceuticals Inc shares are gaining amid a broader market trend of higher daily closes since Friday's close.

16. okt 2026, 20:02 UTC

Xenon Pharmaceuticals Inc shares are declining sharply, continuing a downward trend since Thursday and remaining significantly below their 20-day moving average.

15. okt 2026, 20:03 UTC

Xenon Pharmaceuticals Inc shares are advancing, influenced by a significant upward movement in the Biotechnology sub-sector, despite earlier pulling back from a session high.

14. okt 2026, 19:21 UTC

Xenon Pharmaceuticals Inc shares fell significantly, continuing a downward trend with three consecutive sessions of losses and remaining below its 20-day moving average.

13. okt 2026, 20:01 UTC

Xenon Pharmaceuticals Inc shares fell, breaking a trend of higher daily closes, contrasting with recent upward momentum since Monday's close.

9. okt 2026, 20:06 UTC

Xenon Pharmaceuticals Inc shares are modestly higher, peaking in early afternoon trading.

8. okt 2026, 19:15 UTC

Xenon Pharmaceuticals Inc shares are declining, marking five consecutive sessions lower, and remain significantly below their 20-day moving average amid ongoing market weakness.

6. okt 2026, 20:02 UTC

Xenon Pharmaceuticals Inc shares fell sharply, continuing a downward trend with unusually high volume and remaining below the 20-day moving average.

5. okt 2026, 20:06 UTC

News

Xenon Pharmaceuticals Inc shares are declining, continuing a trend from Friday's close, despite an earlier rebound from a session low.

2. okt 2026, 21:01 UTC

News

Xenon Pharmaceuticals Inc announced equity inducement grants to new employees, with after-market trading showing a slight gain since Friday's close.

1. okt 2026, 23:55 UTC

Xenon Pharmaceuticals Inc declined in after-market trading, moving lower since Thursday's close and remaining significantly below its 20-day moving average.

30. sept 2026, 20:07 UTC

Xenon Pharmaceuticals Inc. shares fell, closing lower than Tuesday's close after an early drop, remaining below its 20-day moving average.

29. sept 2026, 20:01 UTC

Xenon Pharmaceuticals Inc is advancing today with increased trading volume, recovering from earlier losses to reach a peak in late morning.

28. sept 2026, 23:55 UTC

Xenon Pharmaceuticals Inc. is trading lower in after-hours, shifting from a slight gain to a more substantial loss since Monday's close, remaining below its 20-day moving average.

25. sept 2026, 20:01 UTC

Xenon Pharmaceuticals Inc shares fell sharply, pressured by broader biotechnology sector weakness, and are nearly 3% below Thursday's close.

24. sept 2026, 23:35 UTC

Xenon Pharmaceuticals Inc is trading modestly higher in after-market hours, reflecting a cumulative gain since Thursday's close despite a significant decline over the past month.

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

77.64% tõus

12 kuu keskmine prognoos

Keskmine 69.583 USD  77.64%

Kõrge 90 USD

Madal 46 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

16 ratings

15

Osta

1

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
help-icon Live chat